Results 141 to 150 of about 21,002 (228)

Editorial: Emerging targeted and immunotherapeutic strategies in oncology: from solid tumors to hematologic malignancies. [PDF]

Front Pharmacol
Muresan XM, Tigu AB, Roman A, Romani A.
europepmc   +1 more source

Correction: How do Health State Values Differ When Respondents Consider Adults Versus Children Living in Those States? A Systematic Review. [PDF]

Pharmacoeconomics
De Silva A, van Heusden A, Lang Z, Devlin N, Norman R, Dalziel K, Peasgood T, Pan T.   +7 more
europepmc   +1 more source

Response to Letter to the Editor on "Development and validation of PEYRO-Q: a novel multidimensional patient-reported outcome measure for Peyronie's disease". [PDF]

Sex Med
Cocci A, Lo Re M.
europepmc   +1 more source

Pharmacy Benefit Management: Enhancing the Applicability of Pharmacoeconomics for Optimal Decision Making

Previous research indicates that in order to make pharmacoeconomic information applicable and useful for pharmaceutical benefit management (PBM) companies, several aspects need to be considered and improved.
C. Daniel Mullins, Junling Wang
core  

Application of a Prevalence-Adjusted Cost-Effectiveness Threshold Framework for Pulmonary Arterial Hypertension. [PDF]

Pharmacoeconomics
Alsumali A, Pontinha VM, Cohen BG, Levy M, Padula WV.   +4 more
europepmc   +1 more source

Balancing Access and Value in Multi-Indication Medicines: Implications of PD-(L)1 Broad Listings in Australia. [PDF]

Pharmacoeconomics
Luc I, Carter D, Merlin T.
europepmc   +1 more source

A Cost-Effectiveness Analysis for Treatments of Patients with Early Stage Huntington's Disease in the USA. [PDF]

Pharmacoecon Open
Patil D, Slejko JF, Savitt JM, Mattingly Ii TJ.   +3 more
europepmc   +1 more source

Schrodinger's Pricing: Conceptual and Practical Challenges of Conditional PAS in the NICE Technology Appraisal of Lorlatinib for Untreated ALK-Positive Advanced Non-small-cell Lung Cancer (Review of TA1103): An External Assessment Group Perspective. [PDF]

Pharmacoeconomics
Hodgson R, Coughlan D.
europepmc   +1 more source

The costs and benefits of an early access scheme for oncology medicines in Ireland. [PDF]

BMC Health Serv Res
Morris K, Pennington M, Whitelegg C, Parkes L, Mahon R.   +4 more
europepmc   +1 more source

External Validation of SELECT Trial-Derived Cardiovascular Risk Equations in a UK Population with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes. [PDF]

Pharmacoeconomics
Gragnano F, Bøg M, Bojesen AB, Ivkovic M, Lübker C, Fusco F, Baruah R, Whitaker J, Jenkins NC, Lloyd I, Hill S, Weeke PE, Lincoff AM.   +12 more
europepmc   +1 more source